BioStock: PHI expands market potential with regenerative medicine opportunity

October 21, 2022
Language flag

Phase Holographic Imaging’s sales have doubled in one year, according to the company’s annual report published this week. However, it generates even more confidence for the company because PHI now addresses the entire spectrum of the healthcare market, not just medical research. The company aims to become a welded link in the value chain of modern medicine in general and regenerative medicine in particular. To find out more, BioStock contacted the company’s CFO, Patrik Eschricht.

Read the full interview with Patrik Eschricht on biostock.se.

Latest News

Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 2 December 2024

Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an Extraordinary General Meeting on 2 December 2024 at 15.00 CET at the Company’s premises, Skiffervägen 48 in Lund.

PHI resolves on a fully secured rights issue of shares of approximately SEK 64.3 million

The Board of Directors of Phase Holographic Imaging PHI AB has today resolved on a rights issue of shares, with preferential rights for the Company’s existing shareholders, of approximately SEK 64.3 million before deduction of issue related costs, subject to approval by the extraordinary general meeting to be held on 2 December 2024. The purpose of the Rights Issue is to fund a strategic development plan and to strengthen the Company’s capital structure by repayment/off-setting of outstanding loans.

Adopting the final Annual Report

PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members.
See All News